Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A DB Four-Arm, Parallel Group, Proof of Concept, Dose-Finding Adaptive Phase 2a/2b RCT to Investigate the Safety, Tolerability and Efficacy and Effect on QoL of Human Recombinant Alkaline Phosphatase in Patients With Sepsis-Associated AKI

NCT02182440 is registered in ClinicalTrials.gov with AM-Pharma as lead sponsor.

NCT NCT02182440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02182440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A DB Four-Arm, Parallel Group, Proof of Concept, Dose-Finding Adaptive Phase 2a/2b RCT to Investigate the Safety, Tolerability and Efficacy and Effect on QoL of Human Recombinant Alkaline Phosphatase in Patients With Sepsis-Associated AKI
Lead sponsor
AM-Pharma
Phase
Phase 2
Overall status
Completed
Start date
December 18, 2014
Completion date
September 27, 2017
Enrollment
301 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury